A COST-UTILITY ANALYSIS COMPARING TWO SEQUENCES OF TREATMENT FOR FIRST-LINE CHEMOTHERAPY IN METASTATIC PROSTATE CANCER (MCRPC): CABAZITAXEL FOLLOWED BY DOCETAXEL VERSUS DOCETAXEL FOLLOWED BY CABAZITAXEL

Affiliation auteurs!!!! Error affiliation !!!!
TitreA COST-UTILITY ANALYSIS COMPARING TWO SEQUENCES OF TREATMENT FOR FIRST-LINE CHEMOTHERAPY IN METASTATIC PROSTATE CANCER (MCRPC): CABAZITAXEL FOLLOWED BY DOCETAXEL VERSUS DOCETAXEL FOLLOWED BY CABAZITAXEL
Type de publicationJournal Article
Year of Publication2017
AuteursSchwager M., Fizazi K., Zaghdoud N., Delva R., Mescam GG, Baciarello G., Theodore C., Goupil GM, Bompas E., Joly F., Tazi Y., L'Haridon T., N'Guyen T., Barthelemy P., Culine S., Berdah J., Deblock M., Beuzedoc P., Flechon A., Cheneau C., Martineau G., Borget I
JournalVALUE IN HEALTH
Volume20
PaginationA444
Date PublishedOCT-NOV
Type of ArticleMeeting Abstract
ISSN1098-3015
DOI10.1016/j.jval.2017.08.262